Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Angelika Kaufmann

Newcastle AuthorsTitleYearFull text
Lucy Gentles
Bojidar Goranov
Elizabeth Matheson
Dr Ashleigh Herriott
Dr Angelika Kaufmann
et al.
Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types2019
Professor Richard Edmondson
Dr Angelika Kaufmann
Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative2017
Dr Aiste McCormick
Dr Peter Donoghue
Michelle Dixon
Dr Rachel O'Donnell
James Murray
et al.
Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib2017
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Laura Woodhouse
Dr Aiste McCormick
Professor Richard Edmondson
et al.
Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity2016
Dr Aiste McCormick
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents2016
Dr Aiste McCormick
Dr Peter Donoghue
Michelle Dixon
Dr Rachel O'Donnell
Dr Angelika Kaufmann
et al.
Defects in non-homologous end joining pathway in ovarian cancers results in resistance to rucaparib2015
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Aiste McCormick
Professor Nicola Curtin
Professor Richard Edmondson
et al.
Intra- and inter-tumour heterogeneity in epithelial ovarian cancer: consequences for biomarker dependent stratification of therapies2015
Dr Aiste McCormick
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Professor Richard Edmondson
Phosphatase and tensin homolog (PTEN) is a potential target for ovarian cancer sensitisation to cytotoxic agents2015
Dr Aiste McCormick
Michelle Dixon
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Professor Richard Edmondson
et al.
PTEN function is important in determining ovarian cancer sensitivity to cytotoxic agents2015
Dr Angelika Kaufmann
Professor Richard Edmondson
The use of a p53 signature identifies a group of high risk endometrial cancer associated with an excellent prognosis2015
12